Loss of heterozygosis on chromosome 18q21-23 and muscle-invasive bladder cancer natural history

Oncology Letters

Volumn 10, Issue 4, 2015, Pages 2569-2573

  Cai, Tommaso ^a   Mondaini, Nicola ^b   Tiscione, Daniele ^a   Dal Canto, Maurizio ^b   Santi, Raffaella ^b   Bartoletti, Riccardo ^b   Nesi, Gabriella ^b  

^a Hospital Santa Chiara of Trento   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Chromosome 18; Invasive bladder cancer; Loss of heterozygosis; Microsatellite analysis; Urothelial cancer

Indexed keywords

AGED; ARTICLE; ARTIFICIAL NEURAL NETWORK; BLADDER CANCER; BLOOD ANALYSIS; CHROMOSOME 18Q; CLINICAL ARTICLE; CYSTECTOMY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; HETEROZYGOSITY; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSPECTIVE STUDY;

EID: 84940061796     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3616     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
2. Mhawech-Fauceglia P, Cheney RT and Schwaller J: Genetic alterations in urothelial bladder carcinoma: An updated review. Cancer 106: 1205-1216, 2006.
3. Tomasini JM and Konety BR: Urinary markers/cytology: What and when should a urologist use. Urol Clin North Am 40: 165-173, 2013.
4. Cai T, Nesi G, Dal Canto M, Mondaini N, Piazzini M and Bartoletti R: Prognostic role of loss of heterozygosity on chromosome 18 in patients with low-risk nonmuscle-invasive bladder cancer: Results from a prospective study. J Surg Res 161: 89-94, 2010.
5. Bartoletti R, Cai T, Nesi G, Roberta Girardi L, Baroni G and Dal Canto M: Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer. J Surg Res 143: 422-427, 2007.
6. Bartoletti R, Cai T, Dal Canto M, Boddi V, Nesi G and Piazzini M: Multiplex polymerase chain reaction for microsatellite analysis of urine sediment cells: A rapid and inexpensive method for diagnosing and monitoring superficial transitional bladder cell carcinoma. J Urol 175: 2032-2037, 2006.
7. Knowles MA: What we could do now: Molecular pathology of bladder cancer. Mol Pathol 54: 215-221, 2001.
8. Uchida A, Tachibana M, Miyakawa A, Nakamura K and Murai M: Microsatellite analysis in multiple chromosomal regions as a prognostic indicator of primary bladder cancer. Urol Res 28: 297-303, 2000.
9. Switula D: Principles of good clinical practice (GCP) in clinical research. Sci Eng Ethics 6: 71-77, 2000.
10. Polymeropoulos MH, Xiao H and Merril CR: Tetranucleotide repeat polymorphism at the human myelin basic protein gene (MBP). Hum Mol Genet 1: 658, 1992.
11. Bartoletti R, Dal Canto M, Cai T, Piazzini M, Travaglini F, Gavazzi A and Rizzo M: Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment. Oncol Rep 13: 531-537, 2005.
12. Dal Canto M, Bartoletti R, Travaglini F, Piazzini M, Lodovichi G, Rizzo M and Selli C: Molecular urinary sediment analysis in patients with transitional cell bladder carcinoma. Anticancer Res 23: 5095-5100, 2003.
13. Edge SB, Byrd DR, Compton CC, et al (eds): American Joint Committee on Cancer Staging Manual. 7th edition. Springer, New York, NY, pp117-126, 2010.
14. Eble JN, Sauter G, Epstein JI and Sesterhenn IA (eds): World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press, Lyon, France, pp89-154, 2004.
15. Gakis G, Efstathiou J, Lerner SP, et al; International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012: ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol 63: 45-57, 2013.
16. Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A and Witjes JA; European Association of Urology (EAU): Treatment of muscle-invasive and metastatic bladder cancer: Update of the EAU guidelines. Eur Urol 59: 1009-1018, 2011.
17. Cai T, Conti G, Lorenzini M and Bartoletti R: Artificial intelligences in urological practice: The key to success? Ann Oncol 18: 604, 2007.
18. Cai T, Conti G, Nesi G, et al: Artificial intelligence for predicting recurrence-free probability of noninvasive high-grade urothelial bladder cell carcinoma. Oncol Rep 18: 959-964, 2007.
19. Lee SE and Park MS: Prognostic factors for survival in patients with transitional cell carcinoma of the bladder: Evaluation by histopathologic grade, pathologic stage and flow-cytometric analysis. Eur Urol 29: 193-198, 1996.
20. Garcia-Closas M, Ye Y, Rothman N, Figueroa JD, Malats N, Dinney CP, Chatterjee N, Prokunina-Olsson L, Wang Z, Lin J et al: A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Hum Mol Genet 20: 4282-4289, 2011.
21. Koutros S, Baris D, Fischer A, et al: Differential urinary specific gravity as a molecular phenotype of the bladder cancer genetic association in the urea transporter gene, SLC14A1. Int J Cancer 133: 3008-3013, 2013.
22. Brewster SF, Gingell JC, Browne S and Brown KW: Loss of heterozygosity on chromosome 18q is associated with muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer 70: 697-700, 1994.